A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression

Access this Article

Search this Article

Author(s)

    • Hamano Yukako
    • Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
    • Moriwaki Toshikazu
    • Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
    • To Keii
    • Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
    • Watahiki Takahisa
    • Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
    • Yamada Takeshi
    • Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan
    • Sakashita Shingo
    • Department of Pathology, Faculty of Medicine, University of Tsukuba, Japan
    • Hyodo Ichinosuke
    • Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Japan

Abstract

<p>The standard chemotherapies for neuroendocrine tumors (NETs) are somatostatin analog (SSA) and targeted-agents for NET G1/G2 and platinum-based chemotherapy for neuroendocrine carcinoma (NEC), classified according to the WHO criteria of 2010. We report a case of NET, in which tumors were successfully treated with platinum-containing chemotherapy after remarkable progression with SSA. A 46-year-old man with multiple lymph nodes and liver metastases of unknown primary origin was diagnosed with NET G2 based on the examination of a biopsy specimen. His tumors were stable with SSA for a year, but rapidly became enlarged. A second biopsy revealed NEC. He received cisplatin plus etoposide, and his tumors showed a marked reduction in size. </p>

Journal

  • Internal Medicine

    Internal Medicine 58(8), 1087-1091, 2019

    The Japanese Society of Internal Medicine

Codes

Page Top